<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852124</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00040151</org_study_id>
    <secondary_id>1R21AT004089-01A1</secondary_id>
    <nct_id>NCT00852124</nct_id>
  </id_info>
  <brief_title>Safety of VSL#3 in Adult Asthmatics</brief_title>
  <official_title>Safety of VSL#3 for Adult Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are proposing to test the safety of the probiotic, VSL#3, in a placebo controlled double
      blind safety study in 30 asthmatic adults. This adult safety trial was requested by the FDA
      IND review of a pediatric asthma protocol.

      Adults with a doctor diagnosis of persistent asthma will take VSL#3 or placebo twice daily
      for 3 months. Data will be collected, including age, race, height, and weight, present
      medications, past medical history with emphasis on signs/symptoms of asthma.

      On visits to the clinic we will evaluate

        -  Changes in lung function

        -  Intestinal permeability

        -  Intestinal bacteria

        -  Levels of inflammation in the blood

        -  Women will have repeat urine pregnancy testing at each clinic visit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The monitored parameters that will be assessed at each clinic visit or phone call include:

        1. the number of days with asthma related symptoms of cough, wheeze, dyspnea, awakening at
           night, and exercise limitation.

        2. the number of asthma-related missed school/work days

        3. the amount of use of asthma rescue medications

        4. use of non-inhaled steroids

        5. change in medications from baseline visit

        6. diarrhea/liquid stools (&gt; 2/day)

        7. constipation

        8. gas/bloating

        9. fever/chills

       10. scheduled or unscheduled visits for health care

      To monitor for increased risk of safety concerns, we will also inquire on follow up visits
      and phone calls about the following:

      1. household member with immunosuppression such as HIV or chemotherapy.

      On visits to the clinic we will evaluate lung function by spirometry:

        1. change in lung function with spirometry.

        2. women of childbearing potential will have repeat urine pregnancy testing at each clinic
           visit.

        3. intestinal barrier function

        4. intestinal flora

        5. serum inflammatory cytokines and IgE
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate recruitment
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of VSL#3 in Adults Asthmatics</measure>
    <time_frame>3 months</time_frame>
    <description>Change in FEV in adult asthmatics receiving VSL3# as compared to controls receiving placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>VSL#3 2 times daily</description>
    <arm_group_label>VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSL#3 or placebo</intervention_name>
    <description>1 packet 2 x daily of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults age 18-64 years old.

          2. Doctor diagnosis of mild persistent asthma. Persistent asthma is defined by NAEPP
             guidelines as asthma symptoms (cough/wheeze/dyspnea/exercise limitation)of greater
             than 2 times/week daytime or greater than 2 times/month at night over the previous
             month but less than continual and less than 5 nights/week.

          3. FEV1 greater than 60% predicted for age/gender/race/height based on normative data.

          4. No unscheduled asthma related health visit in the 1 month prior to enrollment

          5. School or work days missed less than or equal to 2 in the previous month for asthma.

          6. Albuterol use less than 8 doses (2 puffs or one neb) in past week.

          7. Ability to speak and understand English.

          8. Telephone access.

          9. Women of childbearing potential must confirm that they will use birth control while in
             the study and have a negative urine pregnancy screen at baseline.

        Exclusion Criteria:

          1. Pregnant women, prisoners.

          2. Chronic illness (other than asthma, allergic rhinitis and eczema) such as renal
             disease, diabetes, hypertension or terminal disease or abnormal vital signs: T&gt;
             100.3F, HR&gt;130 bpm, SBP&gt;155 mmHg, or DBP&gt;100 mmHg, RR&gt;25 bpm, or pox&lt;93% room air.

          3. Unable to perform spirometry, necessary for lung function assessment.

          4. Received probiotic in past 6 months.

          5. Subject or household member has immunosuppression such as HIV, history of organ
             transplantation, present cancer or chemotherapy, primary immune disease, or is taking
             an immune modulating drug.

          6. Severe persistent asthmatics who have continual daily or frequent (greater than 5
             nights/week) asthma symptoms and/or FEV1 less than 60% predicted .

          7. Diarrhea or constipation (symptoms more than once in the past week)

          8. Unable to feed orally or to consume cornstarch

          9. Lung disease other than asthma (e.g. COPD, cystic fibrosis, lung cancer,
             bronchiectasis, interstitial lung disease).

         10. Subjects at increased risk of developing infective endocarditis such as those with a
             history of cardiac surgery, IV drug abuse, recent invasive medical procedures or
             dental work (recent = last month).

         11. Allergy to Vancomycin or Cefepime. The parameters of intestinal barrier function,
             intestinal flora, serum inflammatory cytokines, IgE, will have no exclusion ranges as
             these will be collected over time on product as a way of describing the population
             characteristics of study participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio Fasano, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MBRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bienenstock J, Wiley RE, Neigh GS, Waserman S, Keith P. Probiotics in the management and prevention of atopy. Clin Rev Allergy Immunol. 2002 Jun;22(3):275-85. Review.</citation>
    <PMID>12043385</PMID>
  </reference>
  <reference>
    <citation>Hijazi N, Abalkhail B, Seaton A. Diet and childhood asthma in a society in transition: a study in urban and rural Saudi Arabia. Thorax. 2000 Sep;55(9):775-9.</citation>
    <PMID>10950897</PMID>
  </reference>
  <reference>
    <citation>Kalliom√§ki M, Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol. 2003 Feb;3(1):15-20. Review.</citation>
    <PMID>12582309</PMID>
  </reference>
  <reference>
    <citation>Bj√∂rkst√©n B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy. 1999 Mar;29(3):342-6. Erratum in: Clin Exp Allergy 2000 Jul;30(7):1047.</citation>
    <PMID>10202341</PMID>
  </reference>
  <reference>
    <citation>Hijazi Z, Molla AM, Al-Habashi H, Muawad WM, Molla AM, Sharma PN. Intestinal permeability is increased in bronchial asthma. Arch Dis Child. 2004 Mar;89(3):227-9.</citation>
    <PMID>14977697</PMID>
  </reference>
  <reference>
    <citation>Isolauri E, Salminen S; Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. Probiotics: use in allergic disorders: a Nutrition, Allergy, Mucosal Immunology, and Intestinal Microbiota (NAMI) Research Group Report. J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S91-6. doi: 10.1097/MCG.0b013e3181639a98. Review.</citation>
    <PMID>18542035</PMID>
  </reference>
  <reference>
    <citation>Kalliom√§ki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007 Apr;119(4):1019-21. Epub 2007 Feb 7.</citation>
    <PMID>17289135</PMID>
  </reference>
  <reference>
    <citation>Laitinen K, Kalliom√§ki M, Poussa T, Lagstr√∂m H, Isolauri E. Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years. Br J Nutr. 2005 Oct;94(4):565-74.</citation>
    <PMID>16197582</PMID>
  </reference>
  <reference>
    <citation>Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, B√∂hm O, von Kries R. Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy. 2000 Feb;30(2):187-93.</citation>
    <PMID>10651770</PMID>
  </reference>
  <reference>
    <citation>Noverr MC, Noggle RM, Toews GB, Huffnagle GB. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun. 2004 Sep;72(9):4996-5003.</citation>
    <PMID>15321991</PMID>
  </reference>
  <reference>
    <citation>Kalliom√§ki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001 Apr 7;357(9262):1076-9.</citation>
    <PMID>11297958</PMID>
  </reference>
  <reference>
    <citation>Pessi T, S√ºtas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000 Dec;30(12):1804-8.</citation>
    <PMID>11122221</PMID>
  </reference>
  <reference>
    <citation>Isolauri E, S√ºtas Y, Kankaanp√§√§ P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001 Feb;73(2 Suppl):444S-450S. doi: 10.1093/ajcn/73.2.444s. Review.</citation>
    <PMID>11157355</PMID>
  </reference>
  <reference>
    <citation>Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005 Jan;115(1):5-9.</citation>
    <PMID>15629974</PMID>
  </reference>
  <reference>
    <citation>Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005 Jan;115(1):178-81.</citation>
    <PMID>15629999</PMID>
  </reference>
  <reference>
    <citation>Cannon JP, Lee TA, Bolanos JT, Danziger LH. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):31-40. Review.</citation>
    <PMID>15599646</PMID>
  </reference>
  <reference>
    <citation>Rinne M, Kalliomaki M, Arvilommi H, Salminen S, Isolauri E. Effect of probiotics and breastfeeding on the bifidobacterium and lactobacillus/enterococcus microbiota and humoral immune responses. J Pediatr. 2005 Aug;147(2):186-91.</citation>
    <PMID>16126047</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <results_first_submitted>December 2, 2014</results_first_submitted>
  <results_first_submitted_qc>June 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2015</results_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Mucosal Biology Research Center</investigator_full_name>
    <investigator_title>Director Mucosal Biology Research Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Probiotic</keyword>
  <keyword>VSL#3</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between December 2010 and November 2012. Participants were recruited via flyers and newsletters.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Packets similar to VSL#3 taken 2 X daily but not containing active bacteria
VSL#3 or placebo : 1 packet 2 x daily of placebo</description>
        </group>
        <group group_id="P2">
          <title>VSL#3</title>
          <description>Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial)taken 2 x daily in food or a cool beverage.
VSL#3 : VSL#3 2 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Zero participants analyzed for the primary outcome due to early termination of study</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Packets similar to VSL#3 taken 2 X daily but not containing active bacteria
VSL#3 or placebo : 1 packet 2 x daily of placebo</description>
        </group>
        <group group_id="B2">
          <title>VSL#3</title>
          <description>Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial)taken 2 x daily in food or a cool beverage.
VSL#3 : VSL#3 2 times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of VSL#3 in Adults Asthmatics</title>
        <description>Change in FEV in adult asthmatics receiving VSL3# as compared to controls receiving placebo.</description>
        <time_frame>3 months</time_frame>
        <population>3 people were randomized to placebo arm but no data were analyzed due to early termination of study and small number of patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Packets similar to VSL#3 taken 2 X daily but not containing active bacteria
VSL#3 or placebo : 1 packet 2 x daily of placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of VSL#3 in Adults Asthmatics</title>
          <description>Change in FEV in adult asthmatics receiving VSL3# as compared to controls receiving placebo.</description>
          <population>3 people were randomized to placebo arm but no data were analyzed due to early termination of study and small number of patients enrolled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Packets similar to VSL#3 taken 2 X daily but not containing active bacteria
VSL#3 or placebo : 1 packet 2 x daily of placebo</description>
        </group>
        <group group_id="E2">
          <title>VSL#3</title>
          <description>Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial)taken 2 x daily in food or a cool beverage.
VSL#3 : VSL#3 2 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Associated with sinus infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Viral illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to small number of persons recruited before PI relocated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alessio Fasano</name_or_title>
      <organization>UMARYLAND</organization>
      <phone>617-726-1450</phone>
      <email>afasano@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

